Abhita Batra Presents Neuro42 at LSI USA '24

Abhita Batra  0:04  
Neuro 42 is a company which was founded in the year 2020 When we license the technology from Mass General Hospital, and that's where the story started. So I guess everyone knows MRI. Right? So MRI is an established modality for imaging. But do you know that there are long wait times, the patient experiences bad physician experiences Superbad, then we talk about the extensive infrastructure, people are spending up to $10 million to put a new office suite together, they have to ask for favors, you know, when they sign a contract with the hospital, to get into a deal with them so that there is an MR. There, that low availability is not a good market place to be. And that's what we want to change. Let's talk about where we are. And what's our advantage. Neuro 42 provides a point of care benefit for screening patients, not only with stroke, but also for tumor section, we are looking at improving the patient and physician experience here. And not to forget will enhance the possibility of doing live guided imaging. That's never happened before. We are integrating robotics AI NMR, which I'm going to talk about, but that would allow us to do live guided brain biopsy, biopsies, ablation and surgeries that are very much necessary in a surgical theater right now. So this is how our product looks like. It's a portable MRI. It's a beautiful product that has been cleared by FDA already, we plan to have this product adopted in stroke centers, tumor centers, ICUs, emergency centers, we just got the clearance of the product few weeks ago, it's very easy to be wheeled in in any office based setting, you can basically take it to any physician's office, put it next to the bed, have the physician create a space within a few minutes, and patient can lie down get the full set of scan done within 20 minutes. Let's talk about the MRI scans, we talked about the full clinical set being run in 20 minutes. This is the time of the scan it takes for each sequence to run, you know T one under five minutes, which is an achievement for us and T two under five minutes, which is a big deal and flare under nine minutes. They acquired resolution if you look at it, it's 1.5 1.55 mm and the reconstructed is point seven 5.75 2.5 which is comparable to the high field imagers which are out there. So if you look at the images on the right side, they are of the healthy subjects. And if you see the image on the left side, we have an image of a patient with post tumor resection, we can see the pathology I mean, that's the major thing for a low field to compare it with the high Field Imager. The other thing is, are you able to do soft tissue classification. That's the advantage of our lowfield imager. So mean, this is another product that we have in pipeline that we are building at near 42 interventional scanner. It's it's a product that the world has never seen before. We are integrating AI and modern robotics. That design was created with the feedback of neurosurgeons just to allow robotic intervention and free hand movement. You know, of course, we can get into more detail, but let me show you a video. So you can see how the product looks like up close. And we can give a 360 degree view of how the positioning of the robot as the robot goes into that 180 degrees let and the patient lies down next to the bed. The physician is able to co register the robot based on the API and the intelligence that has been integrated into the product. Of course we we would have all of that done in 2026. If you look at how they're going to do the live guided biopsy, they'll have automation incorporated in the robot. We will call register the robot with the patient images prior to prior and during the surgery and then we do the biopsies we do the live guided intervention for DBS shunt placements, this has never been done before. If we talk about AI, this is where we are incorporating the AI. We are creating a tissue classifier and we are making sure that there is predictive analysis incorporated into the product. We want to provide a 360 degree You have the patient in one place in one setting, which is never been done before. If we talk about the product roadmap, we are very much aligned with the timeline we've been talking about since the day we started. We expected to get the clearance in quarter one of this year, we got it. We have our first product ready, we will be launching that product in quarter four of this year. The second product that you just saw, which is the interventional MRI product, has an MRI compatible robot which we license from John Hopkins. It's going to go through verification validation next year, and we expect to incorporate AI in it. We expect to launch that interventional product in 2026. If we talk about IP, and what's unique, right, I mean, we have the IP from John Hopkins, we have the IP from mgh. We have our own IP, we have over 40 patents issued and pending in US, US, India, Japan, China, and many other parts of the world. Which is I think it's a strong IP to start with. If we look at the market, Tam, everyone's interested in Tam, where are we going to focus? What is the market? Is it gonna sell, you know, as the is it worth it? So, um, I mean, we did a huge market analysis. Prior to starting this company. We looked at many markets, TBI, stroke, brain tumors, epilepsy, we decided to focus on stroke cases and brain tumors. Because this is the low hanging fruit for us, we initiate with that we are a billion dollar, you know, we're looking at a billion dollar market right there, each with each indication, even if we capture a small market of it, we will be able to make a big change. That's where we are looking to launch our product, which is the portable MRI this year. So we we are looking at launching as I said in urgent care, stroke centers, tumor centers ICUs. Surgeons love the product. I mean, that's the story that you start with, right if the surgeons don't want the product, it's hard to sell. We have the stakeholders from big institutions, which is UCSF to Mike a lot and to you know, all the big groups that you know of from Mitch burgers of the world, they they love the product, they want not only the portable product, but the interventional product. So we are excited. This is a team that has been supporting me day in day out. We've done it before we are going to do it again. And I have had great experience running companies raising funds, launching products, we raised over a billion dollars in our careers in established companies. Nikhil comes from brain lab with an experience 15 years has done development. He's helped us build this product. Shibu comes from Applied Physics CBCP Ed and his he's basically helping us run the operations. And yeah, we will be launching and moving to commercial. So we are looking at contract manufacturing, and he'll be helping us with that. Hi, Ron comes from Philips Minh found he is helping us in the development of the Mr. These are the projections we have. We expect to sell our portable MRI this year, we expect to be self sufficient by 2026. When we launch interventional, we will make a change and of course we expect more than $70 million in revenue in 2027. This is where we are we've raised over 18 million till now in our life cycle. I mean short span of time, which is three years. We've done our seed series a bridge to Series B we are raising our series B which is 25 million. We expect to close that round pretty soon we we have verbal commitments of fat. If anyone of you know anyone let me know. We are happy to talk. We will be using these funds for not only the development of the product, but launch of the interventional product. And we will go through FDA approval of that product next year as we plan to launch it in 2026. Thank you so much.